Acute Myocarditis: From Pathophysiology to Risk‐Stratified Management—A Clinical Review
Stepwise approach to patients with suspected acute myocarditis, integrating the 2024 American College of Cardiology (ACC) four‐stage classification (Stages A–D) and the 2025 European Society of Cardiology (ESC) inflammatory myopericardial syndrome (IMPS) framework. Step 1 (Initial Assessment): clinical presentation, first‐line investigations (ECG, high‐
Michele Golino +9 more
wiley +1 more source
Cardiac myosin inhibitors - a cutting-edge solution for the management of hypertrophic cardiomyopathy: a narrative review. [PDF]
Younas A +13 more
europepmc +1 more source
Abstract Aquaculture has increasingly turned toward plant extracts' usage as functional additives, owing to their rich content of bioactive compounds that enhance growth performance, boost immune responses, and improve antioxidant capacity in cultured species.
Nader N. Hassona +9 more
wiley +1 more source
Abstract The Cavβ4 subunit of voltage‐gated Cav1.2 channels regulates gene expression in neurons and cardiac cells. It increases the expression of interferon‐β–related genes in H9c2 cardiomyocytes derived from rat ventricular tissue, but the possibility that it also regulates the expression of microRNAs (miRs) remains unexplored.
Elba D. Carrillo +3 more
wiley +1 more source
Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. [PDF]
Hasana U +14 more
europepmc +1 more source
Strategies for the Selection and Application of Biological Scaffolds in Organ‐on‐a‐Chip Systems
Organ‐on‐a‐chip (OoC) serves as a promising microphysiological platform for drug screening, disease modeling, and toxicity assessment. Biomimetic scaffolds are core components that determine the performance of OoC systems by mimicking the in vivo extracellular microenvironment.
Yichi Zhang +8 more
wiley +1 more source
Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition. [PDF]
Govind A.
europepmc +1 more source
Authors' response: septal reduction therapy for obstructive hypertrophic cardiomyopathy. [PDF]
Schelldorfer A, Kutz A, Yakupoglu HY.
europepmc +1 more source
Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with <i>RAF1</i>-associated Noonan syndrome-case report. [PDF]
Seghers HM +4 more
europepmc +1 more source
Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets. [PDF]
Cabré F, Cascante M.
europepmc +1 more source

